Dr. Schecter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
920 US-202 S
Raritan, NJ 08869Phone+1 908-927-3159
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2008 - 2011- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2007
Brown UniversityInternship, Internal Medicine, 2004 - 2005
The Warren Alpert Medical School of Brown UniversityClass of 2004
Certifications & Licensure
NY State Medical License 2006 - 2025
Clinical Trials
- Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma Start of enrollment: 2013 Nov 01
Publications & Presentations
PubMed
- 12 citationsAdjusted comparison of outcomes between patients from CARTITUDE-1multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and ant...Maria-Victoria Mateos, Katja Weisel, Thomas Martin, Jesús G Berdeja, Andrzej Jakubowiak
Haematologica. 2023-08-01 - 26 citationsPhase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/...Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu
Journal of Clinical Oncology. 2023-02-20 - 232 citationsCiltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Fol...Thomas Martin, Saad Z Usmani, Jesus G Berdeja, Mounzer Agha, Adam D Cohen
Journal of Clinical Oncology. 2023-02-20
Abstracts/Posters
- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refr...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R M...Jordan M Schecter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Authored Content
- Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients with Relapsed/Refractory Multiple MyelomaDecember 2021
Press Mentions
DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj) Shows 51 Percent Reduction in Risk of Progression to Active Multiple Myeloma for Patients with High-Risk Smoldering Multiple MyelomaDecember 8th, 2024- Carvykti Lowering Risk of Death as Second-Line Myeloma Therapy: TrialOctober 1st, 2024
- CARVYKTI® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients with Multiple Myeloma as Early as Second LineSeptember 27th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
